Surface Oncology (Surface Oncology) COGS-to-Revenue : 0.00 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Surface Oncology COGS-to-Revenue?

Surface Oncology's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.00 Mil. Its Revenue for the three months ended in Jun. 2023 was $0.00 Mil.

Surface Oncology's COGS to Revenue for the three months ended in Jun. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Surface Oncology's Gross Margin % for the three months ended in Jun. 2023 was N/A%.

Surface Oncology COGS-to-Revenue Historical Data

The historical data trend for Surface Oncology's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surface Oncology COGS-to-Revenue Chart

Surface Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

Surface Oncology Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Surface Oncology COGS-to-Revenue Calculation

Surface Oncology's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	30
	=	0.00

Surface Oncology's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Surface Oncology (NAS:SURF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Surface Oncology's Gross Margin % for the three months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Surface Oncology COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Surface Oncology's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Surface Oncology (Surface Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surface Oncology Inc (NAS:SURF) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 Hampshire Street, 8th Floor, Cambridge, MA, USA, 02139

Website

https://www.surfaceoncology.com

Surface Oncology Inc is a clinical-stage immuno-oncology company. It is developing new therapies that modify the spaces in and around tumors in the tumor microenvironment to create conditions that support and sustain anti-tumor immune responses. The company's pipeline products are SRF231, SRF373, SRF617, and SRF388. Geographically, the activities are carried out throughout the region of the United States.

Executives

Chandra Adams	officer: Deputy GC	SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Alison Oneill	officer: Chief Medical Officer
Jessica Fees	officer: See Remarks	C/O SURFACE ONCOLOGY, ICN., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Robert W. Ross	officer: Chief Medical Officer	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Henry C. Rath	officer: Chief Business Officer	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FL, CAMBRIDGE MA 02139
Vito J. Palombella	officer: Chief Scientific Officer	780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Carsten Brunn	director	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Theresa Boni	officer: General Counsel	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Benjamin Hickey	director	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121
Liisa I Nogelo	officer: General Counsel	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA 02139
Jeff Goater	director, officer: Chief Executive Officer	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David S. Grayzel	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Ix, L.p.	10 percent owner	46 WAREHAM STREET, FLOOR 3, BOSTON MA 02118
Atlas Venture Associates Ix, Llc	10 percent owner	56 WAREHAM STREET, FLOOR 3, BOSTON MA 02118